Quantcast

Latest immunotherapy Stories

2014-09-19 16:24:12

LUBBOCK, Texas, Sept. 19, 2014 /PRNewswire/ -- Kiromic, LLC, a Lubbock bio-pharmaceutical company, announced today the addition of Kent Hance, the former chancellor of Texas Tech University, to its board as the vice chairman. Hance retired as chancellor in July 2014, after raising $1.2 billion for the university. http://photos.prnewswire.com/prnvar/20140919/147303 "Kiromic is pleased to announce that Kent Hance, the most successful chancellor in the history of Texas Tech University,...

2014-09-19 12:25:20

NORWALK, Conn., Sept. 19, 2014 /PRNewswire/ -- UBM Medica US announces that OncoTherapy Network, a leading online community to help oncologists and other clinicians gain a better understanding of the newest information available regarding the use of targeted therapies and immunotherapies, discusses some of the latest news on blood cancer research and treatment. Every September, Blood Cancer Awareness Month is observed as a way to raise awareness about blood cancers--helping to increase...

2014-09-18 08:28:52

MONMOUTH JUNCTION, N.J., Sept. 18, 2014 /PRNewswire/ -- CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company using its CytoSorb® blood purification technology to treat life-threatening inflammatory conditions such as sepsis, is a proud sponsor of: -- World Sepsis Day 2014 organized by the Global Sepsis Alliance -- The short film "97 seconds for sepsis" produced by the Global Sepsis Alliance -- The 3(rd) Annual Celebration of Sepsis Heroes...

2014-09-11 16:28:04

New Facility Poised to Accelerate the Research and Development of Personalized Cellular Cancer Therapies PHILADELPHIA, Sept. 11, 2014 /PRNewswire-USNewswire/ -- The University of Pennsylvania today reached an important milestone in its alliance with Novartis as it unveiled plans for the construction of a first-of-its-kind Center for Advanced Cellular Therapeutics (CACT) on the Penn Medicine campus in Philadelphia. The CACT will become the epicenter for research using Chimeric Antigen...

2014-09-11 08:27:28

-Conference Call and Webcast on September 12, 2014 at 8:30 a.m. ET, 5:30 a.m. PT- MENLO PARK, Calif. and LONDON, Sept. 11, 2014 /PRNewswire/ -- CANCER RESEARCH UK and Cancer Research Technology (CRT), the charity's development and commercialisation arm, have reached an agreement with Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a biotechnology company in the emerging field of regenerative medicine, to take forward Asterias' novel immunotherapy treatment AST-VAC2 into clinical trials in...

2014-09-10 12:28:10

The Emergence of Keytruda--the First PD-1 Inhibitor Approved in the U.S.--is a Significant Milestone in Oncology, According to Decision Resources Group BURLINGTON, Mass., Sept. 10, 2014 /PRNewswire/ -- The recent approval of Merck & Co.'s Keytruda by the U.S. Food and Drug Administration for the treatment of malignant melanoma is a significant milestone for Merck & Co. and for the oncology immunotherapy drug market. Decision Resources Group anticipates the launch of Keytruda as the...

2014-09-05 20:21:03

Horses with melanoma are the subject of this major clinical study TAMPA, Fla., Sept. 5, 2014 /PRNewswire/ -- Morphogenesis Inc., the biotechnology firm developing ImmuneFx(TM), a cancer vaccine that has improved the longevity and quality of life for dogs, cats and horses, announces that a formal equine clinical trial for the direct injection form of the vaccine will begin later this month at a large equine facility in Missouri. Pat Lawman, PhD., co-founder and CEO of Morphogenesis...

2014-09-04 12:26:34

DIEPENBEEK, Belgium, September 4, 2014 /PRNewswire/ -- Scientists discover how to 'switch off' autoimmune diseases Apitope, the drug discovery and development company focused on disease-modifying treatments for patients with autoimmune and allergic diseases, announced today that Bristol University research led by Apitope Founder and CSO, Prof David Wraith, on its treatment approach to autoimmune diseases, such as Multiple Sclerosis (MS), has been published...

2014-09-03 08:35:10

SAN ANTONIO, Sept. 3, 2014 /PRNewswire/ -- United Allergy Services (UAS), a leading healthcare services company that enables family physicians, pediatricians and health systems to deliver safe and effective allergy testing and customized immunotherapy services, today announced that John Thresher has accepted the position of national director of sales. Thresher will be rejoining UAS after a brief stint as vice president of regional development at Airrosti Rehab Centers where he was...

2014-09-03 04:21:54

AMSTERDAM, September 3, 2014 /PRNewswire/ -- ~ Clinical and Business Development expert re-joins the Company ~ Kiadis Pharma B.V. ("Kiadis Pharma", "Kiadis" or "the Company"), a clinical stage biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, today announces the appointment of Dr. Jeroen Rovers, MD PhD, as its Chief Medical Officer. Jeroen Rovers was most recently Chief Medical Officer at Ceronco Biosciences. Prior...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.